NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED

NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED Company Introduction:

NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED is the Indian subsidiary of Nektar Therapeutics, a global biopharmaceutical company headquartered in the United States. Nektar Therapeutics is dedicated to the discovery, development, and commercialization of innovative new drugs for patients suffering from challenging diseases. The company primarily focuses on therapeutic areas such as oncology, immunology, and virology. Utilizing its proprietary polymer conjugate technology platform, Nektar aims to create novel therapeutics designed to enhance efficacy and improve safety profiles. The Indian entity likely supports the parent company's global operations, potentially through research and development activities, clinical trial management, or other strategic functions within the Indian pharmaceutical and biotechnology sector.

Factory or Trader:

NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED is a manufacturer. As a biopharmaceutical company, Nektar Therapeutics is fundamentally involved in the research, development, and production of its own proprietary drug products. This classifies them as a manufacturing entity within the pharmaceutical industry, rather than solely a trader of third-party goods.

The company NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED primarily operates as a research and development center and a support arm for its parent company, Nektar Therapeutics, which is based in the United States.

Therefore, NEKTAR THERAPEUTICS INDIA PRIVATE LIMITED does not directly manufacture or sell commercial pharmaceutical products under its own name in India. Its activities are focused on supporting the global drug development pipeline of Nektar Therapeutics.

Nektar Therapeutics (USA) develops a pipeline of investigational drug candidates, primarily in areas such as oncology and immunology. These candidates are in various stages of clinical development. Examples of such investigational compounds include:

Bempegaldesleukin (NKTR-214)

NKTR-358 (licensed to Eli Lilly)

NKTR-255

These are drug candidates being developed by the parent company, and the Indian subsidiary's role would be related to their clinical development, not their commercial production or direct sale as finished products.